Although the etiology of gastric cancer has been completely obscure for many decades, several considerable advances in the knowledge of the carcinogenesis and development of gastric cancer have been made in the present era. First, it is well known that Helicobacter pylori infection is associated with the carcinogenesis and development of gastric cancer, suggesting that chronic infl ammation may be implicated in the development of intestinal metaplasia and mutations in oncogenes that precede the development of gastric cancer; indeed, the International Agency for Research on Cancer classifi ed H. pylori as a class I human carcinogen in 1994 [2] . Second, the long-suspected infl uence of genetic susceptibility has been elucidated and several polymorphisms of infl ammatory cytokine genes have been implicated as risk factors for gastric cancer [3] [4] [5] [6] [7] .
Introduction
Gastric cancer is the fourth most common cancer and the second most frequent cause of cancer-related deaths, accounting for 10.4% of cancer deaths worldwide [1] .
infectious complications [17] , and excessive surgical stress [18, 19] , factors which result in the production of proinfl ammatory and anti-infl ammatory cytokines, may contribute to a high rate of recurrence and unfavorable long-term survival in various malignancies (Fig. 1) . However, the precise mechanisms remain unclear.
In this review, we focus on the role of humoral mediators produced by cancer cells and/or host immunocompetent cells; in particular, proinfl ammatory and anti-infl ammatory cytokines, in terms of gastric cancer progression and infl uence on host antitumor immunity. Although there is increasing evidence that several polymorphisms of infl ammatory cytokine genes have been implicated as risk factors for gastric cancer, this topic is beyond the scope of this article, but readers are referred to several excellent reviews [4, 5] .
Search strategy
The search strategy in this study was based on previous guidelines for systematic review [20] . Literature databases such as PubMed Medline (National Library of Medicine) and EMBASE were searched from 1980 to 2009. The following medical subject headings were searched: "gastric cancer (or carcinoma)" and "infl ammation", "gastric cancer (or carcinoma)" and "cytokine", "gastric cancer (or carcinoma)" and "mediator", and "gastric cancer (or carcinoma)" and "tumor immunity". In addition, references in the cited articles were reviewed. Using this search, we found 4342 manuscripts, and we selected 812 manuscripts for this review; 804 and 2726 manuscripts were excluded because they were not written in English and manuscript content was not applicable for this review, respectively.
Mechanisms of relationships between cytokines and cancer progression
Increasing evidence is being reported for the hypothesis that several polymorphisms of infl ammatory cytokine genes, such as those for tumor necrosis factor (TNF) and interleukin-1 (IL-1), may increase the risk of gastric cancer [3, 21, 22] . This evidence suggests that several cytokines may contribute to carcinogenesis and cancer progression in gastric cancer. Remarkable advances in molecular medicine have revolutionized the study of carcinogenesis, infl ammatory cytokines, and human immunology. Several possible direct and indirect mechanisms of cytokines contributing to tumor progression may include cytokines directly stimulating carcinogenesis and cancer proliferation, and cytokines locally and/or systemically suppressing host antitumor immunity, thus indirectly leading to cancer progression (Table 1, Fig. 2 ).
TNFα
The critical role of TNFα in infl ammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriasis, is well established, and its tumor-promoting effects have also been demonstrated in animal models [23, 24] . TNFα, produced by malignant cells, leukocytes, and other cells in tumor microenvironments, acts Relationship between cancer progression and various factors associated with the production of proinfl ammatory and anti-infl ammatory cytokines. In the tumor microenvironment, there is a delicate balance between immunocompetent cells and cancer cells through the production of proinfl ammatory and antiinfl ammatory cytokines, which are induced by various factors such as excessive surgical stress, perioperative blood transfusion, postoperative infectious complications, cachexia, aging, and infection of Helicobacter pylori primarily through TNF receptor 1 in an autocrine and a paracrine manner [23] . TNFα promotes DNA damage and inhibits DNA repair by upregulating nitric oxide (NO)-dependent pathways [25] . TNFα can induce the collapse of tumor vasculature and can also promote angiogenesis [26] . Thus, it may contribute to the de velopment of the tissue architecture necessary for tumor growth and metastasis and may induce other cytokines, angiogenic factors, and matrix metalloproteinases (MMPs) to contribute to DNA damage and increase the growth and survival of tumor cells through nuclear factor-κB (NF-κB) pathways [23] . Using a green fl uorescence protein (GFP)-tagged human gastric cancer cell line, Mochizuki et al. [27] demonstrated that the administration of TNFα to mice promoted the progression of peritoneal metastasis.
In the clinical setting, several researchers have reported the clinical signifi cance of serum TNFα levels in patients with gastric cancer. Kabir and Daar [28] reported that the serum level of TNFα was greatly reduced (by approximately one-third) in patients with gastric cancer compared to the level in age-matched controls. Wu et al. [29] did not demonstrate a prognostic value of serum TNFα levels in patients with gastric cancer. However, Forones et al. [30] have demonstrated that patients with stage III or IV gastric cancer had signifi cantly elevated levels of TNFα compared to levels in those with less advanced disease. Thus, the clinical signifi cance of serum TNFα levels in patients with gastric cancer is still controversial. These confl icting fi ndings may be due to the short half-life of TNFα and/or the low sensitivity of commercially available kits for the detection of TNFα.
IL-1
IL-1 is an important cytokine because it possesses several biological properties resulting in the increased expression of proinfl ammatory genes. Several researchers have demonstrated that IL-1α enhances angiogenesis and vascular endothelial cell proliferation in gastric cancer cell lines [31, 32] . Uefuji et al. [33] reported that exogenous IL-1α stimulated cancer cell growth in gastric cancer cell lines, while such growth stimulation was suppressed by an anti-IL-1α antibody or IL-1 receptor antagonist. In the clinical setting, the incidence of IL-1α mRNA expression was signifi cantly higher in patients with pT2-pT4 tumors than in those with pT1 tumors [33] . Tomimatsu et al. [34] demonstrated that the immunohistochemical expression of IL-1α in primary gastric cancer tissue showed a significant correlation with liver metastasis. Furuya et al. [35] also demonstrated that a signifi cantly higher concentration of IL-1α, measured in homogenized tumor samples by enzyme-linked immunosorbent assay, was observed in tumors from patients with liver metastasis than in those from patients without liver metastasis. Hence, IL-1α was suggested to be a potent inducer of tumor cell proliferation and angiogenesis, resulting in tumor progression and hepatic metastasis [35] .
Similar to fi ndings for IL-1α, Beales [36] demonstrated that IL-1β stimulated the proliferation of gastric cancer cell lines, via the receptor-mediated activation of a tyrosine kinase pathway, in a dose-dependent manner. Furthermore, this author [36] revealed that the proliferation activity of IL-1β was signifi cantly reduced by the neutralization of granulocyte macrophage colonystimulating factor (GM-CSF), suggesting that the growth stimulatory action of IL-1β was due to an autocrine intermediary action of GM-CSF. In the clinical setting, the presence of IL-1β genotype polymorphism associated with enhanced IL-1β production signifi cantly increases the risk of gastric cancer and precancerous lesions [37, 38] . Deans et al. [39] reported that tumor IL-1β expression was associated with serum C-reactive protein levels in patients with gastric cancer, an association which resulted in reduced survival.
IL-6
IL-6 is a pleiotropic cytokine produced by a wide variety of cells and it plays important roles both in stimulating B-cell differentiation to antibody-forming plasma cells and in regulating the innate immune response. Ito et al. [40] demonstrated that several gastric cancer cell lines expressed IL-6 mRNA, and it was observed that IL-6 could stimulate gastric cancer cell growth, while anti-IL-6 antibody inhibited this growth. IL-6 secreted from cancer cells combines with IL-6 receptors expressed on the surface of cancer cells. IL-6 and IL-6 receptors act on cancer cells directly via the Janus kinase (JNK)/ signal transducer and activator of transcription 3 pathways [41] . Furthermore, IL-6 may act on cancer cells through hepatocyte growth factor (HGF) by promoting and accelerating invasion as well as lymph node and/or hepatic metastasis [42] . Several authors have demonstrated signifi cant relationships between elevated serum IL-6 levels and tumor stage, depth of tumor, lymphatic invasion, venous invasion, lymph node metastasis, hepatic metastasis, and unfavorable outcome in gastric cancer patients [28, 42, 43] .
IL-10
When fi rst discovered, IL-10 was termed "cytokine synthesis inhibitory factor". IL-10 inhibits the gene expression and synthesis of T-cell and macrophage proinfl ammatory cytokines and suppresses the function of antigen-presenting cells. Very few studies have evaluated the direct role of IL-10 in carcinogenesis. Sugai et al. [44] demonstrated that the intracellular IL-10 level in the monocytes of patients with advanced gastric cancer was signifi cantly increased compared to the levels in patients with early disease or the levels in healthy individuals. Morisaki et al. [45] and Sakamoto et al. [46] reported that gastric cancer tissue expressed IL-10, and its expression was correlated with poor outcomes. There is increasing evidence that higher expression of IL-10 in serum and the peritoneal cavity is associated with the progression of the tumor and prognosis in patients with gastric cancer [47] [48] [49] [50] [51] . These fi ndings suggest that the immunosuppressive properties of IL-10 may contribute to tumor progression through the suppression of host antitumor immunity. Although IL-10 has been recently reported to be a potent angiogenic factor in non-small cell lung carcinoma, it is uncertain whether it exhibits a similar property in gastric cancer [52] .
IL-12
IL-12 is an immunoregulatory cytokine that acts on T cells and natural killer cells. It is also the major cytokine responsible for T-helper type 1 (Th1)-cell differentiation, allowing potent production of interferon gamma (IFNγ). Furthermore, IFNγ has a powerful enhancing effect on the ability of phagocytes and dendritic cells to produce IL-12, thereby creating a potent positive feedback mechanism that promotes strong cell-mediated antitumor immunity [53] .
In the clinical setting, Shibata et al. [54] and Murakami et al. [55] have reported that the production of IL-12 by peripheral blood mononuclear cells (PBMCs), and its serum levels, decrease signifi cantly with advancing stages of cancer, especially in patients with distant metastases. These fi ndings support the hypothesis that the suppression of IL-12 may promote tumor progression through the disruption of host antitumor immunity, although the precise mechanism responsible for the impaired production of IL-12 in the advanced stage of gastric cancer remains unresolved. Nonetheless, cellmediated antitumor immunity seems to be disrupted through the effects of IL-12 and IFNγ in the advanced stage of gastric cancer.
IL-18
IL-18 was fi rst described in 1989 as an IFNγ-inducing factor [56] which was believed to induce the Th1 immune response [57] . Majima et al. [58] had previously indicated that gastric cancers but not colon cancers expressed the IL-18 receptor. In that study, the authors also showed that IL-18 dose-dependently enhanced the proliferation of gastric cancer, which was accompanied by NK-κB activation. Similar results were not observed for colon cancer. Furthermore, when IL-18-pretreated gastric cancer cells were cultured with cytokine-activated peripheral blood killer lymphocytes, the antitumor machineries (perforin and IFNγ production of killer lymphocytes) decreased, resulting in the decreased susceptibility of cancer cells to killer lymphocytes [58] .
In the clinical setting, Kawabata et al. [59] reported that gastric cancer patients with higher IL-18 serum levels experienced a signifi cantly lower survival rate than those who had lower IL-18 serum levels, after undergoing potentially curative resection. IL-18 synergizes with IL-12 for the production of IFNγ and the proliferation of T cells, which may lead to enhanced antitumor immunity [60] . Thus, IL-18 may have paradoxical properties that enhance the proliferation of cancer cells and IL-18-treated cancer cells result in decreased antitumor immunity in gastric cancer.
Transforming growth factor β (TGFβ)
TGFβ, like IL-10, is not only a powerful immunosuppressive and anti-infl ammatory cytokine but is also a central regulator of regulatory T-cell (Treg) proliferation and function [61, 62] . Saito et al. [63] demonstrated that TGFβ1 expression was detected in 22.8% of patients with gastric cancer, in whom the expression was mainly localized in the cytoplasm of carcinoma cells. In addition to its immunosuppressive activity, TGFβ appears to possess pleiotropic functions in terms of gastric cancer progression. Yanagihara and Tsumuraya [64] showed that exogenous TGFβ1-induced cell death occurred by an apoptotic process in human scirrhous-type gastric cancer, but not in nonscirrhous type. Recently, Fu et al. [65] demonstrated that TGFβ promoted the invasion and metastasis of gastric cancer cells via the JNK and extracellular signal-regulated kinase pathway. Inoue et al. [66] reported that TGFβ and HGF produced by gastric fi broblasts stimulated the invasiveness of scirrhous-type gastric cancer cells. In contrast, Komuro et al. [67] demonstrated that the disruption of TGFβ signaling in diffuse-type gastric cancer cells accelerated tumor growth through increased angiogenesis. These discrepant results may be due to the differences in the cancer cell types employed in the studies, i.e., diffuse-or intestinal-type tumors, or the differences in investigated TGFβ signaling subtypes.
Many clinical studies have shown positive correlations of TGFβ1 expression with lymph node metastasis and poor prognosis in gastric cancer [68, 69] . Saito et al. [70] emphasized that there was a strong correlation between TGFβ1 expression and vascular endothelial growth factor (VEGF) expression in gastric cancer tissue, suggesting that tumor progression was promoted indirectly by the stimulation of angiogenesis through the upregulation of VEGF expression in gastric carcinoma.
Another important role of TGFβ is the induction and activation of Tregs, which can inhibit immune responses mediated by CD4 (+) and CD8 (+) T-cells [61, 62] . There is accumulating evidence that increased populations of Tregs are present in patients with gastric cancer [71, 72] . Ichihara et al. [73] demonstrated that populations of Tregs in peripheral blood and TILs were signifi cantly higher in patients with gastric and esophageal cancers than in healthy donors or normal mucosa. Furthermore, Sasada et al. [74] demonstrated that gastric cancer patients with higher percentages of Tregs in PBMCs had signifi cantly poorer prognoses than those with lower percentages of Tregs. In summary, the complex role of TGFβ in direct tumor suppression and progression may be dependent on the stage and cancer cell type, as well as depending on the systemically induced immunosuppressive and anti-infl ammatory properties of this molecule.
Chemokine families
There is accumulating evidence that chemokines play a pivotal role in promoting tumor growth and metastasis in several malignancies [75, 76] . IL-8 has been reported to have mitogenic activity, enhance cell adhesion, and upregulate VEGF and MMP-9 in gastric cancer [77, 78] . In addition, gastric cancer cells in surgical specimens overexpress IL-8 compared to corresponding normal gastric mucosa, and the IL-8 mRNA level is directly correlated with the vascularity of the tumors [79] . Furthermore, the transfection of gastric cancer cells with the IL-8 gene in the gastric wall of nude mice enhanced their tumorigenic and angiogenic potential [80] . Sugasawa et al. [81] have demonstrated that human recombinant CC chemokine ligand 5 (CCL5), also known as RANTES (regulated on activation, normal T cell expressed and secreted) can augment the proliferative capacity of gastric cancer cells in a dose-dependent manner. In that study, it was revealed that the main producer of CCL5 was TILs and not cancer cells. Furthermore, receptors for CCL5 were expressed by cancer cells and not TILs [81, 82] . These fi ndings strongly support the hypothesis that chemokines and chemokine receptors may directly contribute to tumor growth in an autocrine and/or a paracrine fashion, and may also promote tumor metastasis via enhanced angiogenesis and cell adhesion [83] .
Defective T-cell function and IL-12 production by PBMCs in the development of gastric cancer
It is well known that T cells and cytokines produced by innate immune cells play pivotal roles in the host's antitumor immunity. There is increasing evidence that the cytokine production and proliferative capacity of peripheral blood T cells were clearly depressed in the advanced stage of gastric cancer [84] . Jang [85] has demonstrated that the number of Tregs, which regulate the cytokine production and the proliferation of effector T cells, is increased in H. pylori-associated gastritis and gastric cancer tissues. In addition, Shibata et al. [54] demonstrated that the production of IL-12 by PBMCs decreased signifi cantly with advanced stages of gastric cancer, especially in patients with distant metastases. These fi ndings suggest that the depressed antitumor function of effector T cells, which is caused by enhanced Tregs and depressed IL-12 production by PBMCs, may lead to the development of gastric cancer (Fig. 3) .
A paradox of infl ammation and cancer; local infl ammation and systemic anti-infl ammation in the development of gastric cancer
In terms of infl ammatory reactions, neoplastic disorders constitute a paradox. Immunocompetent cells associated with tumors, and the tumor cells themselves, produce infl ammatory cytokines and chemokines, resulting in tumors being infi ltrated by leukocytes. However, neoplastic disorders are associated with a defective capacity to mount infl ammatory reactions at sites other than the tumor, and circulating monocytes from cancer patients are defective in their capacity to respond to chemoattractants [86] . Cancer cells can grow by escaping the attack of immune cells by disrupting the host immune system, which is progressively suppressed as a result of tumor progression and metastasis [87] .
Various locally produced factors originating in the tumor microenvironment may contribute to the systemic anti-infl ammation associated with cancer (Fig. 2) . Infl ammatory cytokines and chemokines leaking into the systemic circulation are likely to desensitize circulating leukocytes. The serum and local expressions of proinfl ammatory and anti-infl ammatory cytokines in relation to the development of gastric cancer are summarized in Table 2 . In patients with advanced gastric cancer, most cytokines, except for IFNγ and IL-12, both of which enhance or suppress host antitumor immunity, appear to have increased serum and local expression levels. The manner in which the local cytokine network 
Concluding remarks and suggestions for future work
When host-mediated antitumor activity is weaker than tumor-mediated immunity, tumor cells undergo immune escape and grow rapidly. However, when the hostmediated antitumor immunity is stronger than the tumor-mediated immunosuppressive activity, tumor cells are eliminated. The net outcome of a persistent infl ammatory microenvironment is enhanced tumor promotion, accelerated tumor progression, invasion of the surrounding tissues, angiogenesis, and often metastasis [88] .
However, for all the local infl ammation in tumors, in many cases the overall innate immunity of the host is reduced. The challenge for the future is to normalize the infl ammatory network to regain a normal host response overall, by decreasing the high levels of tumor-promoting molecules, such as proinfl ammatory cytokines, in infi ltrating cells and increasing their levels of tumorsuppressing molecules, such as anti-infl ammatory cytokines. In this manner, we can harness activities that are antitumor and suppress those that are protumor.
Despite continuous progress in the development of conventional therapies such as surgery, chemotherapy, and radiotherapy, as well as novel target-protein-based cancer therapy, gastric cancer is still the most lethal cancer in Asia. Emerging modalities provide promise to combat this malignancy [89] . Besides these treatment strategies, clinical trials of cytokine-based therapy have been performed in several malignancies [11] . However, proinfl ammatory or anti-infl ammatory treatments for gastric cancer have been considered a double-edged sword. Several infl ammatory cytokines; for example, IL-18, are known to be responsible for Th1-cell differentiation, which enhances antitumor immunity; however, they cause enhanced proliferation of gastric cancer cells [58] . A more detailed understanding of the differential roles of malignant cell-derived and host-derived cytokines at different stages of the malignant process could, consequently, open new avenues for the manipulation of cytokine expression and function in immunotherapy for gastric cancer.
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